Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects

Inclusion Criteria: * Healthy subjects aged between 18 and 45 years (inclusive) at screening * BMI between 18 and 28 kg/m2 (inclusive) and bodyweight at least 50 kg at screening * systolic blood pressure: 100-140 mmHg, diastolic blood pressure: 60-90 mmHg and heart rate: 45-90 bpm (inclusive), measured on the leading arm, in the supine position at screening * No clinically significant findings on the physical examination at screening * Signed informed consent prior to any study-mandated procedure * Hematology and clinical chemistry results not deviating from the normal range to clinically relevant extent at screening * Ability to communicate well with the investigator to understand and comply with the requirements of the study Exclusion Criteria: * Smoking \>5 cigarettes per day * History or clinical evidence of alcoholism or drug abuse within the 3- year period prior to screening * Loss of ≥250 ml of blood within 3 months prior to screening. Treatment with an investigational drug within 30 days prior to screening * Previous systemic treatment with any prescribed or over the counter medication (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of the study * Inability to stop consumption inducing food products (e.g. grapefruit juice) 72 h before start of the study * Excessive caffeine consumption (\>8 cups of coffee/ 8l coca cola per day) * Legal incapacity or limited legal capacity at screening * Positive results from urine drug screen at screening * History or clinical evidence of any disease (e.g. gastrointestinal disease: Morbus Crohn, Colitis Ulcerosa, anamnestic gastrointestinal bleeding) and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity * Known hypersensitivity to Metamizole (Novalgin®) or excipients of the drug formulation * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.